Free News Archives
Latest Issue of OR Manager
May 2025

Analysis finds unplanned returns to the OR overestimated

Editor's Note In this single institution study, the most common reasons for unplanned return to the OR (uROR) were infection and hemorrhage. However, the researchers found that a large number of cases were incorrectly classified as uROR, when they were instead planned reoperations without adequate documentation. Using uROR as reported…

Read More

By: Judy Mathias
June 21, 2017
Share

Joint Commission redesigns ESC form

Editor's Note The Joint Commission announced on June 21 a redesign of its Evidence of Standards Compliance (ESC) form. The form was redesigned to help organizations focus on describing the critical aspects of corrective actions they have taken to resolve Requirements for Improvement, and to help ensure sustainability of those…

Read More

By: Judy Mathias
June 21, 2017
Share

FDA: Alvogen recalls seven lots of clindamycin

Editor's Note The Food and Drug Administration (FDA) on June 16 announced the recall by Alvogen/Hospira Inc, a Pfizer company, of seven lots of Clindamycin Injection USP ADD-Vantage Vials. The recall was initiated because microbial growth was detected during a routine simulation of the manufacturing process, which represents the potential…

Read More

By: Judy Mathias
June 21, 2017
Share

Surgical ‘ICU boarders’ get less attention from physicians, caregivers

Editor's Note Surgical ICU patients boarding in alternative ICUs because of overcrowding are often seen at the end of rounds, receive fewer face-to-face assessments from physicians, and are given less bedside attention by ICU provider teams, this study finds. The researchers found that: caregivers spent about 16% less time on…

Read More

By: Judy Mathias
June 20, 2017
Share

Ambulatory services market to grow 5.8% by 2024

Editor's Note The global ambulatory services market was valued at $2.3 trillion in 2016 and is forecast to grow to $3.7 trillion by 2024, according to a new study by Ameri Research. In 2016, primary care offices accounted for the majority of market share at more than 48% because they…

Read More

By: Judy Mathias
June 20, 2017
Share

FDA: Maquet/Datascope recalls certain Intra-Aortic Balloon Pumps

Editor's Note The Food and Drug Administration (FDA) on June 19 announced the recall by Maquet/Datascope (Fairfield, New Jersey) of its System CS100, CS100i, and CS300 Intra-Aortic Balloon Pumps. The recall also applies to System 98 or System 98XT IABP that was converted to a CS100i or CS 300 IABP.…

Read More

By: Judy Mathias
June 20, 2017
Share

Study: Ureteroscopes remain contaminated after cleaning, sterilization

Editor's Note Techniques used to clean and sterilize flexible ureteroscopes left behind contamination that included debris, residue, and bacteria, in this study presented June 14 at the 44th Annual Conference of the Association for Professionals in Infection Control. Researchers with Ofstead & Associates (St Paul, Minnesota) sampled 16 ureteroscopes at…

Read More

By: Judy Mathias
June 19, 2017
Share

New guideline targets total joint infections

Editor's Note The American College of Rheumatology (ACR) and American Association of Hip and Knee Surgeons (AAHKS) have released a new guideline to help reduce postoperative total hip and knee infections through the perioperative management of antirheumatic medications. Among the recommendations: Discontinuing biologic therapy before surgery in patients with inflammatory…

Read More

By: Judy Mathias
June 19, 2017
Share

FDA: Hospira recalls Sodium Bicarbonate, Quelicin, and Potassium Phosphates injections

Editor's Note The Food and Drug Administration (FDA) on June 16 announced the recall by Hospira, Inc, a Pfizer company, of the following: 42 lots of 8.4% Sodium Bicarbonate Injection, USP, 50 mL vials 5 lots of Neut (Sodium Bicarbonate 4% additive solution) 5 mL vials 5 lots of Quelicin…

Read More

By: Judy Mathias
June 19, 2017
Share

Value-based purchasing not linked to improvements in quality

Editor's Note In this study, Medicare’s Hospital Value-Based Purchasing (HVBP) program was not associated with improvements in quality measures of clinical process or patient experience. HVBP also was not associated with a significant reduction in two of three mortality measures (ie, acute myocardial infarction or heart failure). It was associated…

Read More

By: Judy Mathias
June 16, 2017
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat